Sarbajit Mukherjee

Medical Oncology
2023 Buffalo Spree Top Doctors Badge

Dr. Mukherjee is a Buffalo Spree Top Doctor! See all of our physicians who made this year's list.

Top Doctors 2023

Cancers Treated:

Specializing In:

Esophageal Cancer Gastric Cancer Neuroendocrine Tumors Colon Cancer

Research Interests:

Use of immune checkpoint inhibitors in solid tumors

About Sarbajit Mukherjee


I am a gastrointestinal medical oncologist with a research focus on novel clinical trials and cancer immunotherapy. I have gained experience in translational research and clinical trial design through a Master's program in clinical and translational science. My current work involves understanding the biology of gastrointestinal cancers and designing novel clinical trials to improve patient outcomes. Besides, I am interested in studying mechanisms of immune dysfunction in obese cancer patients and the use of immune checkpoint inhibitors in solid tumors. I have led over a dozen clinical trials as a Principal Investigator (PI) and received six grants as a PI or co-investigator. Many of my studies are investigator-initiated and grant-funded through national organizations like the National Cancer Institute (NCI) and the department of defense (DOD). My work has resulted in several national/international presentations and peer-reviewed publications in high-impact journals. As a physician-scientist, my goal is to conduct innovative clinical trials using novel immunotherapy agents and take discoveries from the lab to the bedside to improve life expectancy as well as the quality of life of cancer patients. As an educator, I strive to improve the quality of oncology education and mentor the next generation of clinician investigators.

I have had the opportunity to serve the American Society of Clinical Oncology (ASCO). I have been a member of the Trainee Council Working Group, Clinical Practice Guidelines Committee, and the Professional Development Committee at ASCO. I have also served on multiple guidelines panels for ASCO. Currently, I am a guidelines panel member at the National Comprehensive Cancer Network(NCCN) and the International Society for Diseases of the Esophagus. I also serve as a member of the board of directors at the Esophageal Cancer Action Network and as a co-chair of the quality subcommittee at the Society for Immunotherapy of Cancer.

I have been fortunate to receive many national and international awards. I have been asked to review manuscripts for reputed journals and grant applications for federal funding agencies.

For me, caring for a cancer patient is more than treating a disease; it's a healing process involving both the patient's body, mind, and caregivers. I would like to see myself as a successful clinical and translational researcher and a compassionate physician, and a thought leader in the field of gastrointestinal cancers.


Roswell Park Comprehensive Cancer

  • Assistant Professor of Oncology
  • Assistant Professor of Immunology
  • Department of Medicine
  • Co-Leader, GI Translational Research Group

Jacobs School of Medicine and Biomedical Sciences, University at Buffalo

  • Assistant Professor


Education and Training:

  • 2010 - MD - Nilratan Sircar Medical College, West Bengal University of Health Sciences, India
  • 2018 - MS - Master of Science in Clinical and Translational Science, University of Oklahoma, Oklahoma City, OK


  • 2012-2015 - Saint Joseph Hospital, Chicago, IL


  • 2015-2018 - University of Oklahoma Health Sciences Center, Oklahoma City, OK

Board Certification:

  • 2018 - Medical Oncology - American Board of Internal Medicine
  • 2018 - Hematology - American Board of Internal Medicine
  • 2015 - Internal Medicine - American Board of Internal Medicine

Professional Memberships:

  • Society for Immunotherapy of Cancer
  • American Association for Cancer Research
  • American College of Gastroenterology
  • North American Neuroendocrine Tumor Society
  • European Society of Medical Oncology
  • American Society of Clinical Oncology

Professional Experience:

  • 2021-present - Quality Subcommittee, Society for Immunotherapy of Cancer (SITC)
  • 2021-present - Guidelines committee, International Society of the Diseases of the Esophagus
  • 2018-present - Member, Occult Primary Panel, NCCN
  • 2018-present - Board of Directors, Esophageal Cancer Action Network
  • 2017-2018 - Chief fellow, Hematology-Oncology, University of Oklahoma
  • 2017-2018 - Clinical Practice Guidelines Committee, ASCO
  • 2016-2018 - Professional Development Committee, ASCO

Honors & Awards:

  • Clinical Investigator Scholarship Award, North American Neuroendocrine Tumor Society
  • ASCO/AACR Methods in Clinical Cancer Workshop, Vail, CO
  • James N. George award for the outstanding fellow in hematology-oncology, University of Oklahoma
  • Gold Humanism Honor Society
  • Conquer Cancer Foundation Merit Award, ASCO
  • Alpha Omega Alpha (AOA) Honor Medical Society
  • Early Career Reviewer, Developmental Therapeutics (DT), Center for Scientific Review, National Institutes of Health
  • Society for Immunotherapy of Cancer (SITC) Clinical Immuno-Oncology Network (SCION) Workshop participant
  • Young Investigator Award, ESMO World Congress on Gastrointestinal Cancer

Clinical Trials

Featured on Cancer Talk


Full Publications list on PubMed

1. Mukherjee S, Seager RJ, Lee YH, Conroy JM, Kalinski P, Pabla S. Tumor Inflammation, Obesity, and Proliferative Status as Biomarkers in Gastroesophageal Adenocarcinoma. J Pers Med. 2021 Dec 7;11(12):1324. PMID: 34945796.

2. Deng L, Groman A, Jiang C, Perimbeti S, Gabriel E, Kukar M, Mukherjee S. Association of Preoperative Chemosensitivity With Postoperative Survival in Patients With Resected Gastric Adenocarcinoma. JAMA Netw Open. 2021 Nov 1;4(11): e2135340. PMID: 34797369.

3. Malhotra U*, Mukherjee S*, Fountzilas C, Boland P, Miller A, Patnaik S, Attwood K, Yendamuri S, Adjei A, Kannisto E, Opyrchal M, Bushunow P, Loud P, Iyer R, Khushalani NI. Pralatrexate in combination with oxaliplatin in advanced esophago-gastric cancer: a phase II trial with predictive molecular correlates. Mol Cancer Ther. 2020 Jan;19(1):304-311.PubMed PMID: 31575653. *co-first author

4. Mukherjee S, Fountzilas C, Boland PM, Gosain R, Attwood K, Tan W, Khushalani N, Iyer R. Phase I Study of Irinotecan/5-Fluorouracil/Leucovorin (FOLFIRI) with Sunitinib for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma. Target Oncol. 2019 Dec 4. PubMed PMID: 31802410.

5. Wang Z, Aguilar EG, Luna JI, Dunai C, Khuat LT, Le CT, Mirsoian A, Minnar CM, Stoffel KM, Sturgill IR, Grossenbacher SK, Withers SS, Rebhun RB, Hartigan-O'Connor DJ, Méndez-Lagares G, Tarantal AF, Isseroff RR, Griffith TS, Schalper KA, Merleev A, Saha A, Maverakis E, Kelly K, Aljumaily R, Ibrahimi S, Mukherjee S, Machiorlatti M, Vesely SK, Longo DL, Blazar BR, Canter RJ, Murphy WJ, Monjazeb AM. Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade. Nat Med. 2019 Jan; 25(1):141-151. PubMed PMID: 30420753.